TOPIRAMATE | A215638 | XIAMEN LP PHARMACUETICAL CO LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Upsher-Smith Laboratories, LLC v. Xiamen LP Pharmaceutical Co., Ltd. 4 patentsANDA 215638topiramate | D. Del. | 2023-02-23 | Terminated 2024-07-29 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$11.23
per ea
Lowest NADAC/Unit
$2.66
per ea
Brand NDCs
0
Generic NDCs
5
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 69680018130TOPIRAMATE ER 200 MG SPRINK CAP | $11.23 | EA | Generic | — | 2026-06-17 |
| 69680018030TOPIRAMATE ER 150 MG SPRINK CAP | $8.83 | EA | Generic | — | 2026-06-17 |
| 69680017930TOPIRAMATE ER 100 MG SPRINK CAP | $5.60 | EA | Generic | — | 2026-06-17 |
| 69680017830TOPIRAMATE ER 50 MG SPRINKL CAP | $3.66 | EA | Generic | — | 2026-06-17 |
| 69680017730TOPIRAMATE ER 25 MG SPRINKL CAP | $2.66 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.